Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Renal & Urology News3d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Nature4y
G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes
G-protein coupled receptors ... and insulin/glucagon secretion are GPCRs, which in islets mediate the effects of many of the circulating factors, such as glucagon-like peptide-1, free fatty ...